# US 2018/0022794 A1 · Anti-rho gtpase conformational single domain antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0022794 A1
- Document ID: US20180022794A1
- Status: Published application
- Kind: A1
- Application number: 15/548,578
- Filed: 2016-02-02
- Published: 2018-01-25
- Earliest claimed: 2015-02-03
- Assignees: Inserm (Institut National De La Sante Et De La Recherche Medicale); Universite Paul Sabatier Toulouse III; Institut Claudius Regaud
- Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale); Universite Paul Sabatier Toulouse III; Institut Claudius Regaud
- Inventors: Aurelien OLICHON; Laura KELLER; Gilles FAVRE; Nicolas BERY; Patrick CHINESTRA
- Web page: https://patentgrep.com/patent/US20180022794A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/12: Viral antigens
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/40: against enzymes
- C12N 15/85: for animal cells
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/80: remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
- C07K 2317/82: functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/95: containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
- C12N 2015/8518: {expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to active form specific anti-Rho GTPase conformational single domain antibodies and their uses in particular in the therapeutic and diagnostic fields. In particular, the present invention relates to a single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT have at least 90% of identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody which are defined in Table B.

## Claims

### Claim 1

A single domain antibody wherein the amino acid sequences of CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the single domain antibody have at least 90% identity with the amino acid sequences of the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibodies of Table B.

### Claim 2 (depends on 1)

The single domain antibody of claim 1 which comprises the CDR1-IMGT, CDR2-IMGT and CDR3-IMGT of the H12, B6, 4P75, 4SP1, 4SNP36, 4SNP61, 5SP10, 5SP11, 5SP58, 5SNP47, 5SNP48, 5SNP65, B20, B15, B5, B71, E3, A6, G12, NB61, 212B, 111B or 404F (hs2dAb) single domain antibody.

### Claim 3 (depends on 1)

The single domain antibody of claim 1 which comprises a framework region FR1 having at least 90% identity with SEQ ID NO:1.

### Claim 4 (depends on 1)

The single domain antibody of claim 1 which comprises a framework region FR2 having at least 90% identity with SEQ ID NO:2.

### Claim 5 (depends on 1)

The single domain antibody of claim 1 which comprises a framework region FR3 having at least 90% identity with SEQ ID NO:3.

### Claim 6 (depends on 1)

The single domain antibody of claim 1 which comprises a framework region FR4 having at least 90% identity with SEQ ID NO:4.

### Claim 7 (depends on 1)

The single domain antibody of claim 1 which comprises an amino acid sequence having at least 70% identity with an amino acid sequence selected from the group consisting of SEQ ID NO:62-80 and SEQ ID NO: 93-96.

### Claim 8 (depends on 1)

The single domain antibody of claim 1 which comprises an amino acid sequence selected from the group consisting of the amino acid sequences represented by SEQ ID NO:62-80 and SEQ ID NO: 93-96.

### Claim 9 (depends on 1)

The single domain antibody of claim 1 which is fused to a heterologous polypeptide to form a fusion protein.

### Claim 10 (depends on 1)

The single domain antibody of claim 1 which is fused to an immunoglobulin domain, a single domain antibody, a carrier polypeptide, a fluorescent polypeptide, an enzyme, a polypeptide that facilitates purification or isolation of the fusion protein, a cell-penetrating peptide or an ubiquitin ligase domain.

### Claim 11 (depends on 1)

The single domain antibody of claim 1 which is fused to a F-box domain.

### Claim 12 (depends on 1)

A nucleic acid molecule which encodes for the single domain antibody of claim 1; or a vector which comprises the nucleic acid molecule; or a host cell transformed with the nucleic acid molecule.

### Claim at position 13

13-14. (canceled)

### Claim 15 (depends on 1)

A method of detecting the presence of at least one activated form of a Rho GTPase, comprising the steps of i) obtaining a sample from a subject, ii) contacting, in vitro, the sample with a single domain antibody of claim 1, iii) detecting the binding of said single domain antibody to said sample, and iv) comparing the binding detected in step (iii) with a standard, wherein a difference in binding relative to said standard indicates the presence of the at least one activated form of the Rho GTPase in the sample.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

A method for treating cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of the single domain antibody of claim 1 or a nucleic acid molecule encoding the single domain antibody.
